Rob Zenilman submits: Normalized net profit margins in the Biotech sector for the most recently reported quarter ranged from 41.4% (GILD) down to -182.6% (INCY), with a median value of 5.0%
Note: Normalized net income includes the effect of taxes, but excludes any unusual items.
Data in table version -- click on a ticker for opinion and analysis of the company:
| Total | Norm. Net | Norm. Net | |||
|---|---|---|---|---|---|
| Quarter | Revenue | Profit | Profit | ||
| Ticker | Company | Ending | ($mm) | ($mm) | Margin (%) |
| AFFX | Affymetrix Inc. | 03/31/06 | $86.39 | $4.35 | 5.0%
|
| ALXN | Alexion Pharmaceutic | 03/31/06 | $0.77 | -$17.07 | N/A
|
| AMGN | Amgen Inc. | 03/31/06 | $3217.00 | $896.00 | 27.9%
|
| AMLN | Amylin Pharmaceutica | 03/31/06 | $82.35 | -$31.56 | -38.3%
|
| BIIB | Biogen Idec Inc. | 03/31/06 | $427.80 | $158.60 | 37.1%
|
| BMRN | BioMarin Pharmaceuti | 03/31/06 | $13.81 | -$4.10 | -29.7%
|
| BSTE | Biosite Incorporated | 03/31/06 | $79.33 | $18.44 | 23.2%
|
| CELG | Celgene Corporation | 03/31/06 | $181.84 | $36.24 | 19.9%
|
| DNA | Genentech Inc. | 03/31/06 | $1986.00 | $504.00 | 25.4%
|
| ELN | Elan Corp. plc | 03/31/06 | $134.30 | -$36.36 | -27.1%
|
| GILD | Gilead Sciences Inc. | 03/31/06 | $692.88 | $286.62 | 41.4%
|
| GPRO | Gen-Probe Inc. | 03/31/06 | $86.26 | $19.08 | 22.1%
|
| IMCL | Imclone Systems Inc. | 03/31/06 | $245.13 | $95.20 | 38.8%
|
| INCY | Incyte Corp. | 03/31/06 | $6.47 | -$11.80 | -182.6%
|
| ISTA | ISTA Pharmaceuticals | 03/31/06 | $5.55 | -$6.09 | -109.8%
|
| KOSP | KOS Pharmaceuticals | 03/31/06 | $170.77 | $7.91 | 4.6%
|
| MEDI | MedImmune Inc. | 03/31/06 | $498.00 | $68.64 | 13.8%
|
| NABI | Nabi Biopharmaceutic | 04/01/06 | $27.55 | -$11.30 | -41.0%
|
| NBIX | Neurocrine Bioscienc | 03/31/06 | $19.48 | -$9.39 | -48.2%
|
| ONXX | Onyx Pharmaceuticals | 03/31/06 | N/A | -$9.09 | N/A
|
| PGNX | Progenics Pharmaceut | 03/31/06 | $11.00 | $0.55 | 5.0%
|
| PHRM | Pharmion Corp. | 03/31/06 | $56.59 | $2.62 | 4.6%
|
| TELK | Telik Inc. | 03/31/06 | N/A | -$8.92 | N/A
|
| VRTX | Vertex Pharmaceutica | 03/31/06 | $39.09 | -$23.35 | -59.7% |
Data: CapitalIQ
Related:
- Most recent opinion and analysis of Biotech stocks
- Full transcripts of recent conference calls in the Biotech sector
- Add the Biotech Stock Blog to your My Yahoo! page
Aside: Did you know that Seeking Alpha now publishes a daily recap of Jim Cramer's Mad Money stock picks?
